Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
Cheng WangLong YuanXiujuan WuYan WangHao TianGuozhi ZhangAndi WanSiyi XiongChengfang WangYuqin ZhouDandan MaYangqiu BaoMan QuJun JiangYi ZhangXiaowei QiPublished in: BMC medicine (2024)
Neoadjuvant taxane plus lobaplatin has shown better efficacy than taxane plus anthracycline, and both regimens have similar toxicity profiles. This trial may provide a reference for a better combination strategy of immunotherapy in NAC for TNBC in the future.
Keyphrases
- locally advanced
- phase ii study
- neoadjuvant chemotherapy
- rectal cancer
- metastatic breast cancer
- squamous cell carcinoma
- radiation therapy
- lymph node
- sentinel lymph node
- transcription factor
- clinical trial
- study protocol
- oxidative stress
- phase iii
- open label
- phase ii
- randomized controlled trial
- current status
- early stage
- oxide nanoparticles